Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split

Arrowhead Pharmaceuticals released positive late-stage trial results for its RNA interference drug plozasiran (Redemplo) in severe hypertriglyceridemia, highlighting a strong safety profile and a more convenient dosing schedule compared to rival Ionis Pharmaceuticals' Tryngolza. Arrowhead plans a supplemental FDA submission later this year to expand the drug's indication.

This Wire brief sits within Fusion42's coverage of Biotech.